(MENAFN- PR Newswire) CAMBRIDGE, Mass., April 15, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan's 8th
Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30.
Daniel Getts, Ph.D., Chief Executive Officer of Myeloid, will participate in a fireside chat on Monday, April 29, 2024, at 11:30 am ET.
Company management will also participate in one-on-one meetings with investors during the event.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage immunology company,
engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases.
Myeloid is headquartered in Cambridge, MA.
For additional information, please visit,
and follow us on
LinkedIn
and
X/Twitter .
Investor Contact
Amy Conrad
Juniper Point
[email protected]
SOURCE Myeloid Therapeutics
MENAFN15042024003732001241ID1108097615
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.